- Roche Canada announced that Canada’s Drug Agency (CDA-AMC) has recommended public reimbursement of Gazyva (obinutuzumab) for adults with active lupus nephritis receiving standard therapy, following Health Canada’s approval earlier this year.
- Lupus nephritis is a serious kidney complication of systemic lupus erythematosus (SLE), affecting nearly 40% of Canadians living with lupus and potentially leading to kidney damage or kidney failure.
- The recommendation was backed by data from the Phase III REGENCY trial, where 46.4% of patients treated with Gazyva plus standard therapy achieved complete renal response versus 33.1% with standard therapy alone. The study also showed reduced corticosteroid use and improved proteinuria outcomes.
- Roche said the positive recommendation is an important step toward expanding patient access and that it will continue working with provinces and territories to secure reimbursement through public and private drug plans across Canada.
Takeaways:
Gazyva’s reimbursement recommendation is a clear commercial win for Roche because it opens the door to public coverage in a high-need, specialty autoimmune market. If provinces adopt it, the drug could become a new standard option for lupus nephritis patients who need better kidney outcomes than standard therapy alone.
The bigger market implication is that Roche can now push deeper into Canada’s immunology space with a premium biologic backed by strong Phase III data, while also building momentum for wider provincial and private-plan access. Because lupus nephritis is serious and long-term, reimbursement would likely support steady uptake rather than a one-time spike.
Source: CA Newswire
